NCE-1 Intelligence & Market Opportunity

Sotyktu

Deucravacitinib

Immunomodulators

Oral Tablet

Approval Date

09-Sep-22

NCE-1 Date

09-Sep-26

NCE Date

09-Sep-27

Commercial snapshot

Market performance & projections

Revenue ($M)

291

CAGR (%)

0.165

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

342

2027

414

2028

481

2029

536

2030

587

2031

631

2032

670

Molecule profile

Details & specifications

Molecule

Deucravacitinib

Innovator

E.R. SQUIBB & SONS, L.L.C.

Dosage Form

Oral Tablet

Strength

6 mg

Therapeutic Category

Immunomodulators

Usage

To treat moderate-to-severe plaque psoriasis

Good to know

Frequently asked questions

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.